FDA approves Lembaz as first treatment shown to extend survival in infantile-onset Niemann-Pick disease type C

The FDA has approved Lembaz for patients with infantile-onset Niemann–Pick disease type C, following evidence of extended survival in a rare and progressive neurological disorder.
On 17 November 2026, the US Food and Drug Administration approved Lembaz (adrabetadex) to reduce the risk of death in adults and children weighing at least 7 kg whose neurological symptoms of Niemann–Pick disease type C began before the age of six.
FDA-reviewed evidence involving 36 treated patients showed a 55% reduction in the risk of death compared with matched external controls, with median survival of 8.5 versus 4.9 years; the intrathecal medicine carries a boxed warning for hearing impairment, including permanent hearing loss, and is the first NPC treatment shown to extend survival rather than the first medicine approved for the disease overall.
Field | Content |
Company | Not specified in supplied source summary |
Medicine | Lembaz (adrabetadex) |
Regulatory Authority | US Food and Drug Administration |
Approval Date | 17 November 2026 |
Approval Type | New treatment approval |
Therapeutic Area | Rare neurological diseases |
Indication | Infantile-onset Niemann–Pick disease type C |
Eligible Patients | Adults and children weighing at least 7 kg with neurological symptom onset before age six |
Treatment Objective | Reduce the risk of death |
Administration | Intrathecal |
Clinical Evidence | FDA-reviewed evidence from 36 treated patients compared with matched external controls |
Survival Benefit | 55% reduction in risk of death versus matched external controls |
Median Survival | 8.5 years with treatment versus 4.9 years in matched external controls |
Key Safety Warning | Boxed warning for hearing impairment including permanent hearing loss |
Regulatory Significance | First NPC treatment shown to extend survival; not the first NPC medicine approved overall |
Clinical Implications | Provides a survival-focused treatment option for eligible patients with early-onset neurological disease |
Primary Source | https://www.fda.gov/news-events/press-announcements/fda-approves-first-drug-shown-help-patients-infantile-onset-niemann-pick-disease-type-c-live-longer |
Discover how nuaxia can support your next medical education initiative:
Find out more about our specialist services - Moore's Outcome Assessments, Educational Needs Assessments and Patient Impact Studies for the Medical Education sector
Contact us on: support@nuaxia.com


コメント